Triple threat: new drug and radiation combo takes on lung cancer
NCT ID NCT07271602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a special type of radiation (quad shot radiotherapy) to a new immunotherapy drug (QL1706) plus chemotherapy can better control advanced non-small cell lung cancer. About 104 people with stage IV lung cancer that has not been treated yet will take part. The goal is to see if the combination shrinks tumors and delays cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?